| Popis: |
Although reperfusion of ischemic myocardium is crucial for myocardial salvage, reperfusion-mediated ventricular dysfunction and arrhythmias may affect the outcome of coronary artery recanalization or surgical revascularization. In the clinical setting, prolonged recovery period is frequently observed during which the heart may require support using catecholamines and/or assist devices. Pharmacologic interventions capable of shortening this period of vulnerability have significant clinical significance. Infusion of exogenous adenosine has been shown to provide cardioprotection in models of coronary artery occlusion (1–5). Several mechanisms have been postulated to explain cardioprotective actions of exogenous adenosine and adenosine promoting agents, such as acadesine, including increased blood flow (6), activation of A1-receptors (7) and/or ATP-sensitive potassium channels (8), prevention of ATP depletion (9,10); reduction of catecholamine release (11); diminished calcium entry (12); inhibition of neutrophils (13), and decreased platelet (14) activation. Adenosine and adenosine derivatives also are known to inhibit phosphodiesterase activity (15). |
